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Edited by Jesus AvilaAbstract Neuritic plaques are the key pathological feature of
Alzheimer’s disease, and amyloid b (Ab) peptides are major com-
ponent of these plaques. In this study, we demonstrated the inﬂu-
ence of aluminum (Al) on the Ab peptide degradation by
cathepsin D. Al did not directly aﬀect the cathepsin D activity
using small synthetic substrate. However, when Ab peptides were
used as substrate, the apparent inhibitory eﬀect of Al on cathep-
sin D activity was observed. This inhibitory eﬀect disappeared by
treatment of desferrioxamine. These results indicate that Al has
the potential to interact and disrupt Ab peptide catabolism via
the inhibition of proteolytic degradation.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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There are many reports which show that Al causes inhibition
of various protein functions and enzymes activities [1]. Partic-
ularly, Al seems to be a risk factor for various neurotoxic dis-
eases caused by suppression of protein degradation [2].
Therefore, the inﬂuence of Al on protease activity is notable
for the study of its neurotoxicity.
Earlier studies have suggested that Al inhibited calpain-med-
iated proteolysis of human neuroﬁlament [3] and also inhibited
trypsin and a-chymotrypsin proteolytic activity [4]. Kor-
chazhkina et al. [5] recently reported that Al was able to inhibit
plasmin degradation of the Ab peptide (Ab25–35). Their results
indicated that inhibitory eﬀect of Al was caused by a direct
interaction between Al and plasmin. Although many other
Ab degrading enzymes exert their action in extracellular media
at neutral pH, some studies have demonstrated that Ab pep-
tide accumulation may occur within the intracellular matrixAbbreviations: AD, Alzheimer’s disease; Ab, amyloid b; CD, circular
dichroism; DFO, desferrioxamine; ICP-MS, inductively coupled plas-
ma mass spectrometry; MES, 2-morpholinoethanesulfonic acid; TCA,
trichloroacetic acid; TFA, triﬂuoroacetic acid
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doi:10.1016/j.febslet.2006.10.075[6–11]. This leads to the consideration that Ab peptide is
deposited and causes a core of neuritic plaques after cell death.
Furthermore, Nakanishi described the pathological roles of
neuronal and microglial cathepsins in brain aging and age-re-
lated diseases [12,13]. Indeed, recent reports indicated that Ab
peptide was taken up predominantly by microglia via class A
scavenger receptors and the class B scavenger receptor type I
[14,15]. Subsequently, the internalized Ab peptides were accu-
mulated and degraded in the lysosomes of microglia [16].
These observations strongly suggest that phagocytosed Ab
peptides are mainly degraded by cathepsin D in lysosomes.
Cathepsin D is a typical aspartic protease in lysosome and
functions primarily to degrade proteins by bulk proteolysis
in the acidic milieu. Although the optimal pH of cathepsin D
is approximately pH 3.5, it is likely that limited proteolysis is
exerted by cathepsins in a less acidic intracellular compartment
such as early and late endosomes [13].
Alternatively, previous studies using neuroblastoma cells
[17] or rat cortical neurons [18] have described Al endocytosis
with subsequent subcellular localization in lysosomes. More-
over, Xie et al. [19] reported that Al localized to the lysosomes
in hippocampal pyramidal neurons in Al-loaded rabbits. We
then considered that Al could exist as a soluble form when it
is taken into the lysosome, which is a weakly acidic matrix.
Therefore, it is possible that Al interacts with various proteins
and internalized substrates within lysosomes.
In the present study, we focused on the eﬀect of Al toward
cathepsin D, a candidate enzyme in Ab peptide degradation
[20,21]. Our main objective was to evaluate whether Al might
aﬀect the proteolysis of proteins, including Ab1–40 and Ab1–42
peptide, by cathepsin D in an acidic matrix. Our overall pur-
pose is to resolve a possible participation of Al in the accumu-
lation of pathological proteins such as Ab peptide and to
propose a novel mechanism of Al-induced neurotoxicity.2. Materials and methods
2.1. Direct eﬀect of Al on cathepsin D activity
A synthetic peptide substrate used to assay of cathepsin D, (7-Meth-
oxycoumarin-4-yl) acetyl-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys
(Dnp)-D-Arg-NH3, was purchased from Peptide Institute, Inc. (Osaka,
Japan). This synthetic substrate was dissolved in DMSO and diluted to
0.2 mM in 50 mM acetate buﬀer (pH 4.0). Human liver cathepsin D
(Calbiochem, CA, USA) was dissolved in 0.1 M 2-morpholinoethane-
sulfonic acid (MES) buﬀer (pH 4.5) at 18 U/ml. Five microliter ofblished by Elsevier B.V. All rights reserved.
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Fig. 1. The direct eﬀects on cathepsin D activity by Al. The ﬁnal Al
concentrations were 0.1 and 0.2 mM in the reaction mixture. Analysis
was performed to determine the ﬂuorescence at an excitation wave-
length of 328 nm and emission wavelength of 393 nm using a synthetic
peptide substrate. Values are means ± S.D. (n = 4).
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sin D solution, and was incubated at 37 C for 20 h. Following this,
5 ll of 0.2 mM synthetic peptide substrate and 35 ll of 50 mM acetate
buﬀer (pH 4.0) were added to the cathepsin D and Al mixture, fol-
lowed by incubation at 37 C for 10 min. The reaction was stopped
by rapid cooling on ice followed by the addition of an equal volume
of ice-cold 5% trichloroacetic acid (TCA) solution. After centrifuga-
tion at 10000 · g for 5 min, the ﬂuorescence intensity of the superna-
tant was monitored at excitation and emission frequencies of 328 nm
and 393 nm, respectively.
2.2. Indirect eﬀect of Al on degradation of substrates by cathepsin D
2.2.1. Degradation of acid-denatured hemoglobin. Acid-denatured
hemoglobin, which is a typical substrate of cathepsin D, was prepared
by the method of Schwabe [22]. Cathepsin D activity was determined
by the method of Rosenfeld et al. [23] with minor modiﬁcation. 20 ll
of various concentrations of AlCl3 solution was added to 0.5 ml of ace-
tate buﬀer (pH 3.5) containing acid-denatured hemoglobin, and this
was incubated at 37 C for 30 min. Next, 20 ll of cathepsin D (25 U/
ml) was added to the mixture, followed by incubation at 37 C for
30 min. The reaction was stopped by the addition of an equal volume
of ice-cold 5% TCA. After centrifugation at 10000 · g for 5 min, the
supernatant samples were measured by the Folin–Lowry method.
2.2.2. Degradation of Ab1–40 and Ab1–42 peptides. When the Ab pep-
tide was used as a substrate for cathepsin D, 0.5 mg/ml of synthetic
Ab1–40 and Ab1–42 peptides (Bachem, Bubendorf, Switzerland) were
incubated at 37 C for 60 min with various concentration of AlCl3,
FeCl3, and ZnCl2 in 0.1 M MES buﬀer (pH 4.5). Next, 4.2 ll of
150 U/ml cathepsin D in 0.1 M MES buﬀer (pH 4.5) was added to
20 ll of the mixture. After further incubation at 37 C for 20 h, the
reaction was stopped by adding an equal volume of 1,1,1,3,3,3-hexaﬂu-
oro-2-propanol, which acts as a strong denaturant of Ab peptides by
breaking their steoric structures and inducing the formation of a-heli-
ces [24] containing 0.2% triﬂuoroacetic acid (TFA). After centrifuga-
tion at 4 C, 15000 · g for 3 min at 4 C, a portion of the
supernatant was applied to reverse phase HPLC.
2.2.3. Determination of Ab1–40 and Ab1–42 peptides by HPLC. The
proteolytic degradation of Ab peptides was determined using reverse
phase HPLC as described Hamazaki [20] and McDermott and Gibson
[21] with minor modiﬁcations. We used an Inertsil 300 C8 column
(4.6 · 100 mm, 5 lm, GL Science, Tokyo, Japan) for Ab1–40 peptide,
and a ZORBAX 300SB-C18 column (4.6 · 150 mm, 5 lm, Agilent,
USA) for Ab1–42 peptide. To analyze Ab1–40 peptide degradation,
the column temperature was maintained at 30 C, with an injection
volume of 50 ll. The Ab1–40 peptide was eluted at 26 min with a
40 min-linear gradient from 0% to 60% acetonitrile in 0.1% TFA using
a ﬂow rate of 1 ml/min; this was detected using UV absorbance at
215 nm. In contrast, determination of Ab1–42 peptide degradation
was performed with the column temperature maintained at 40 C;
the injection volume remained at 50 ll. A mobile phase gradient was
used for Ab1–42 peptide elution; the population of acetonitrile was in-
creased from 20% to 60% over 25 min in 0.1% TFA using a ﬂow rate of
1 ml/min, with UV detection at 220 nm. Under these conditions, Ab1–
42 peptide was eluted in 15 min. All elutions were fractionated and
applied to the protein sequencer to conﬁrm the formation of amyloid
fragments. Sequencing of peptides was performed using Protein
Sequencer (PPSQ-21 A, Shimazu, Japan).
2.3. Eﬀect of DFO on the inhibition of Ab1–40 and Ab1–42 peptide
degradation by Al
After preincubation of Ab peptides with Al, 1 mM desferrioxamine
desferrioxamine (DFO) was added to the mixture. Following this, the
degradation of the peptide was performed by adding cathepsin D and
incubating for 20 h. Degradation of both Ab1–40 and Ab1–42 peptides in
the presence and absence of DFO was observed by the HPLC method
described above.
2.4. Circular dichroism spectroscopy
The circular dichroism (CD) spectrum was measured using a Jasco J-
820 spectropolarimeter (Tokyo, Japan). The mixture containing
0.5 mM Al and 0.5 mg/ml Ab peptide in 0.1 M MES buﬀer (pH 4.5)
was loaded into a cylindrical cell (0.5 mm path length) for measure-
ments in the UV range of 190–260 nm (scan speed 20 nm/min). The
nitrogen gas ﬂow rate was set at 5 L/min. Repetitive scans were usedto improve the signal-to-noise ratio, and an average of four scans
was performed.
2.5. Analysis of Al bound to various peptides
Ten microliter of 4 mg/ml Ab1–40 peptide, aprotinin (Sigma-Aldrich,
MO, USA), or glucagon (Sigma-Aldrich) was added to 10 ll of
1.0 mM AlCl3 in 0.1 M MES buﬀer (pH 4.5); the mixture was then
incubated at 37 C for 60 min. Next, the solution was applied to a
polyvinylidene diﬂuoride (PVDF) membrane cartridge (ProSorb, Ap-
plied Biosystems, USA) for a protein sequence assay apparatus. The
membrane and inside of the tube were washed with 0.5 ml of 0.1 M
MES buﬀer (pH 4.5) ﬁve times to remove excess free Al; Al bound
to peptides on the PVDF membrane was recovered using 0.5 ml of
1 mM DFO aqua solution. Al content was determined by inductively
coupled plasma mass spectrometry (ICP-MS) (Sciex Elan DRC II,
Perkin-Elmer, USA).
2.6. Statistical analysis
All experimental data are shown as means ± S.D. Data were ana-
lyzed using Student’s t-test and analysis of variance (ANOVA) fol-
lowed by Bonferroni correction. In all statistical analyses, the levels
of signiﬁcant diﬀerences were identiﬁed by P < 0.05.3. Results
3.1. Direct eﬀect of Al on cathepsin D activity
We evaluated the direct eﬀect of Al on cathepsin D activity a
using synthetic low molecular weight substrate. When cathep-
sin D was preincubated with Al (0.125–0.5 mM) and then
added to a synthetic low molecular weight substrate, cathepsin
D activity was not signiﬁcantly aﬀected as compared to the
control value generated without preincubation with Al (Fig. 1).
3.2. Inﬂuence of Al-pretreatment to substrates of cathepsin D
First, we examined the indirect inﬂuence of Al on cathepsin
D activity using acid-denatured hemoglobin as the substrate.
As shown in Fig. 2, after preincubation with 0.2, 0.5, and
1.0 mM Al for 30 min at 37 C, the apparent degradation of
acid-denatured hemoglobin was signiﬁcantly decreased at
8.5 ± 5.3%, 31.0 ± 5.6%, and 72.8 ± 6.8% versus control
(n = 6), respectively.
Subsequently, the eﬀect of pretreatment with Al was exam-
ined using Ab peptides as substrates for degradation by
cathepsin D. Chromatograms of Ab peptide clearly demon-
strated that incubation with cathepsin D led to degradation
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Fig. 2. Indirect eﬀects of Al on degradation of acid-denatured
hemoglobin by cathepsin D. The ﬁnal Al concentrations were 0.2,
0.5, and 1.0 mM in the reaction mixture. Values are means ± S.D.
(n = 6). Signiﬁcantly diﬀerent from control; P < 0.01 (*).
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Fig. 3. Chromatograms of the degradation of Ab1–40 peptide by
cathepsin D. (A) Ab1–40. (B) Ab1–40 digested by cathepsin D. (C)
Pretreated Ab1–40 with 0.5 mM Al following digestion by cathepsin D.
(D) Pretreated Ab1–40 with 0.5 mM Al followed by incubation with
DFO for 30 min and subsequent digestion by cathepsin D. After
incubation, the samples were analyzed on HPLC; all eluent (0–26 ml)
were collected (1 ml/tube) for peptide identiﬁcation. The new products
of degradation were identiﬁed using protein sequencer.
T. Sakamoto et al. / FEBS Letters 580 (2006) 6543–6549 6545of Ab1–40 (Fig. 3B) and Ab1–42 peptides (Fig. 4B). The digested
fragments from each Ab peptide were recovered as shown in
Figs. 3B and 4B. Although Ab1–19 and Ab20–34 were conﬁrmed
in the eluent from Ab1–40 peptide, only Ab1–19 was identiﬁed
from Ab1–42 peptide under our HPLC conditions in order to
quantify the amount of residual Ab1–40 or Ab1–42 peptide.
However, when the each Ab peptide was pretreated with Al,
Fe, or Zn (at a level about 0.25 mM), the degradation of
Ab1–40 and Ab1–42 peptides by cathepsin D was signiﬁcantly
inhibited by pretreatment of Al above 0.25 mM (Figs. 3C
and 4C). In addition, the inhibitory eﬀect of Al was more
obvious than that of Fe and Zn (Tables 1 and 2). As shown
in Table 1, when compared to the control, the degradation
of the Ab1–40 peptide by cathepsin D was inhibited by
21.2 ± 17.4%, 45.0 ± 9.7%, and 46.9 ± 15.9% with pretreat-
ment of Al at 0.125, 0.25, and 0.5 mM, respectively. Also,
signiﬁcant inhibition of the Ab1–42 peptide was observed when
pretreated with Al at 0.25 mM and 0.5 mM (Table 2).
3.3. Inﬂuence of DFO on the inhibitory eﬀect of Al for
degradation of Ab peptides by cathepsin D
Degradation of the Ab1–40 peptide (Fig. 3D) and Ab1–42 pep-
tide (Fig. 4D) by cathepsin D was recovered by addition of
1 mM DFO following pre-incubation of Ab with Al. The inhi-
bition ratio induced by pretreatment with 0.5 mM Al was re-
duced from 46.9% to 10.4% for Ab1–40 peptide degradation
using 1 mM DFO treatment, while the inhibitory eﬀect caused
by Al pretreatment on the degradation of Ab1–42 peptide was
almost eliminated by treatment with 1 mM DFO.
3.4. Alteration of the secondary structure of Ab peptides induced
by the pretreatment with Al
To investigate the mechanism of Al inhibitory of cathepsin
D-mediated Ab peptide degradation, we performed a second-
ary structure analysis in solution using CD spectroscopy.
Under the previously stated conditions, conformational
changes were not observed in either the Ab1–40 or Ab1–42 pep-
tides in the presence of 0.5 mM Al after at least 20 h of incu-
bation at 37 C, pH 4.5 (Fig. 5).
3.5. Binding of Al to Ab1–40 peptide
Furthermore, to investigate the mechanism by which Al
inhibits the degradation of Ab peptide by cathepsin D, we at-tempted to demonstrate binding Al to the Ab peptide after incu-
bationwithAb peptide under weakly acidic conditions (pH 4.5).
In this experiment, we conﬁrmed that free Al3+ was not precip-
itated by determining the concentration ofAl in the ﬁltered solu-
tion obtained from the control sample (with the vehicle
containing 0.5 mM Al). Indeed, the control showed that free
Al3+ was not retained on the membrane after washing with an
acidic buﬀer (pH 4.5) (Fig. 6). Al bound to the Ab1–40 peptide,
aprotinin, or glucagon on the PVDF membrane was released
using DFO, and the recovered Al amounts were determined.
As shown in Fig. 6, the Al content bound to the Ab1–40 peptide
was more signiﬁcant than that of aprotinin and glucagon.4. Discussion
Ab peptides are core constituents of the neuritic (senile) pla-
ques, one of the typical neuropathological changes of Alzhei-
mer’s disease (AD) [25,26]. It has been widely viewed that
AD might arise from an imbalance in the rate of synthesis
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Fig. 4. Chromatograms of the degradation of Ab1–42 peptide by
cathepsin D. (A) Ab1–42. (B) Ab1–42 digested by cathepsin D. (C)
Pretreated Ab1–42 with 0.5 mMAl followed by digestion with cathepsin
D. (D) Pretreated Ab1–42 with 0.5 mM Al followed by incubation with
DFO for 30 min and subsequent digestion by cathepsin D. After
incubation the samples were analyzed on HPLC; all eluent (0–15 ml)
were collected (1 ml/tube) for peptide identiﬁcation. The new products
of degradation were identiﬁed using protein sequencer.
Table 1
Inhibitory eﬀect of Al, Fe, and Zn on Ab1–40 peptide degradation by
cathepsin D
Concentration (mM) Inhibition (%)
Al Fe Zn
0.125 21.2 ± 17.4 – –
0.25 45.0 ± 9.7 ** 1.1 ± 1.9 0.2 ± 0.3
0.50 46.9 ± 15.7** 38.9 ± 7.3* 5.8 ± 5.4
Each data represents mean values ± S.D. (n = 3–5). The inhibition (%)
of degradation by Al, Fe, and Zn are calculated by dividing the peak
area of Ab1–40 peptide in the presence of each metal by the corre-
sponding peak areas obtained in the absence of each metal. Signiﬁcant
diﬀerences from control value: (–) indicates not done.
*P < 0.05.
**P < 0.001.
Table 2
Inhibitory eﬀect of Al, Fe, and Zn on Ab1–42 peptide degradation by
cathepsin D
Concentration (mM) Inhibition (%)
Al Fe Zn
0.125 60 – –
0.25 36.7 ± 13.7 * 60 60
0.50 36.7 ± 8.4 ** 60 60
Each data represents mean values ± S.D. (n = 3–5). The inhibition (%)
of degradation by Al, Fe, and Zn are calculated by dividing the peak
area of Ab1–42 peptide in the presence of each metal by the corre-
sponding peak areas obtained in the absence of each metal. Signiﬁcant
diﬀerences from control value: (–) indicates not done.
*P < 0.05.
**P < 0.001.
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PVDF membrane for protein sequence assay. Al bound to Ab1–40,
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normal metabolism, Ab peptide levels appear to be strictly reg-
ulated, resulting in a low level of Ab peptide and no deposition
T. Sakamoto et al. / FEBS Letters 580 (2006) 6543–6549 6547in the brain. Therefore, it is considered that a failure in a pro-
teolytic function causes accumulation of Ab peptide. Several
proteases have been shown to be capable of cleaving Ab pep-
tide. There are number of candidate proteases, including tryp-
sin and a-chymotrypsin [27], insulin degrading enzyme [28–30],
endothelin-converting enzyme [31], carboxypeptidase B [32],
angiotensin-converting enzyme [33], plasmin [34,35], neprilysin
[36] and cathepsin D [20,21]. However, the enzyme deﬁnitively
responsible for the physiological degradation of Ab peptide is
thus far unclear.
Because soluble Al3+ is markedly increased in acidic matri-
ces, we examined the inﬂuence of Al on the activity of lyso-
somal cathepsin D-mediated proteolysis of Ab peptides.
When a synthetic decapeptide substrate was used, direct inter-
action was not observed between Al and human cathepsin D.
In addition, Falkous et al. [37] did not ﬁnd signiﬁcant direct
eﬀects of Al to lysosomal protease when synthetic small pep-
tides were used as substrate. However, degradation of acid-
denatured hemoglobin and Ab peptides by cathepsin D was
signiﬁcantly inhibited when Al was pretreated with the cathep-
sin D substrates. This apparent inhibition likely indicates that
acid-denatured hemoglobin interacts with Al3+ to form com-
plexes which are not easily degraded by cathepsin D. There-
fore, we further examined the potential of Al to induce
substrate intensively toward decomposition by cathepsin D
using Ab peptides.
We observed the inhibitory eﬀects of Fe and Zn as well as Al
on the Ab peptide degradation by cathepsin D using HPLC
[20,21]. Sample preparation containing 1,1,1,3,3,3-hexaﬂu-
oro-2-propanol and TFA gave good recovery of Ab peptides
without aggregation. Ab1–40 and Ab1–42 peptides could be
detected quantitatively HPLC under conditions used in this
study. Fe and Zn showed only a slight inhibitory eﬀect on
Ab peptide degradation when compared to Al under same con-
ditions. Although Mantyh et al. [38] and Kawahara et al. [39–
41] demonstrated that Al, Fe, and Zn enhanced the aggrega-
tion of the Ab1–40 peptide, we did not observe aggregation of
the Ab peptides following their incubation with 0.5 mM Al
for 20 h at 37 C, pH 4.5. Thus, based on the observed interac-
tion between Al and Ab peptides, the inhibitory eﬀect of Al
appears to be speciﬁc for acidic conditions.
In order to evaluate the apparent inhibitory eﬀect of Al for
Ab degradation by cathepsin D, we ﬁrst estimated whether Al
treatment caused a conformational change in the Ab peptides,
resulting in resistance towards cathepsin D. Some researchers
have reported that Al accelerated the conformational changes
of Ab peptide from random to b-sheet form [42–44]. We ob-
served the conformation of Ab1–40 and Ab1–42 peptides in
the presence of Al under acidic conditions and no changes in
secondary structure of Ab were observed, at least within the
20 h of incubation at pH 4.5. However, our reaction conditions
(e.g. pH and incubation time) diﬀer from that done in previous
studies.
Next, we investigated another inhibitory mechanism by
which Al could inhibit Ab peptide degradation by cathepsin
D. From the results shown in Tables 1 and 2, Ab peptide seems
to be tolerant to cathepsin D when bound to Al under soluble
conditions. Addition of DFO prior to cathepsin D degradation
caused a disappearance of the inhibitory eﬀect by Al on Ab
peptides degradation; this suggests that Al exerted its eﬀects
via reversible interaction with the Ab peptide. This result also
indicates that a chelating agent like Clioquinol [45,46] may beeﬀective for the treatment of Alzheimer’s disease, if Al partic-
ipates in the pathophysiology of the disease. Since these results
strongly indicate that Al associated with Ab as soluble com-
plex at pH 4.5, we attempted to determine if a signiﬁcant
amount of Al bound to the peptides using a PVDF membrane
technique. In general, the propensity for Al3+ to be bound by
biological ligands such as carboxylate at acidic pH will be
lower than at neutral pH. However, our results clearly
demonstrated that Al bound easily to Ab1–40 peptides at a
physiologically-relevant pH 4.0–5.0 (i.e. that of the lysosomal
fraction in the brain). Recently, Vyas et al. [47] indicated using
27Al nuclear magnetic resonance spectroscopy and amino acid
sequencing of Ab peptides in the presence of Al that Al3+ ions
could interact with Ab1–40 and Ab6–25 peptides. Their data also
showed the possibility that Asp7, His14, and Asp23 have under-
gone steric interference associated with aqueous Al3+ to form a
relatively stable complex. Moreover, they revealed that the Ab
peptide is stably bound by Al at pH 4.0–6.0 via its sites at
Asp7, His14, and Asp23, which undergo steric interference
Al3+ ion-complexation. This observation supports our result
that Al has binding potential to the Ab peptides in acid matrix.
On the other hand, cathepsin D cleaves the Ab peptide at
Phe19-Phe20 and Leu34-Met35 [20,21]. Therefore, it is possible
that the steric interaction between Al and Ab peptides may af-
fect the digestion of Ab peptides by disturbing the cleavage
sites for cathepsin D, even before aggregation of the Ab pep-
tide occurs. As the resultant, it can be considered that Al in-
duces the depositition of Ab peptides via its inhibitory
potential against Ab degradation by cathepsin D.
In a previous report, we showed that the relationship be-
tween Al accumulation and the acceleration of lipid peroxida-
tion in the rat brain [48]. Interestingly, recent studies clearly
suggest that neurotoxicity exerted by senile plaques arises from
the induction of oxidative stress [49–51]. Furthermore, Pratico
et al. [52] reported that Al increased in vivo lipid peroxidation,
as well as Al-accelerated Ab peptide formation and plaque
deposition in amyloid precursor protein transgenic mice.
Therefore, it seems important to establish the relationship be-
tween the acceleration of lipid peroxidation and plaque depo-
sition induced by Al.
In conclusion, Al inhibits the degradation of some substrates
of cathepsin D. Therefore, it is proposed that Al triggers the
intracellular accumulation of proteins and peptides, including
Ab peptide, if cathepsin D participates its degradation
in vivo. Although the mechanisms of AD pathogenesis have
not been fully elucidated, increasing evidence indicates that
the accumulation of Ab peptides might cause the formation
of the neuritic plaques, and the neurotoxicity that results are
due to the generation of radical oxygen species [49–51]. Thus,
the inhibitory potential of Al towards cathepsin D presented
here can be considered a toxic feature of Al, which may be a
risk factor of AD-like pathogenesis through the deposit of neu-
ritic plaque.References
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